Eversept Partners LP Sells 2,115,170 Shares of Esperion Therapeutics, Inc. $ESPR

Eversept Partners LP reduced its stake in Esperion Therapeutics, Inc. (NASDAQ:ESPR) by 54.9% during the first quarter, according to its most recent filing with the SEC. The fund owned 1,735,963 shares of the biopharmaceutical company’s stock after selling 2,115,170 shares during the quarter. Eversept Partners LP owned 0.67% of Esperion Therapeutics worth $4,757,000 at the end of the most recent quarter.

Other institutional investors also recently added to or reduced their stakes in the company. Jones Financial Companies Lllp bought a new stake in Esperion Therapeutics in the first quarter worth about $278,000. Sivia Capital Partners LLC purchased a new position in Esperion Therapeutics in the second quarter valued at about $25,000. Geode Capital Management LLC grew its position in shares of Esperion Therapeutics by 3.1% during the 2nd quarter. Geode Capital Management LLC now owns 4,583,988 shares of the biopharmaceutical company’s stock valued at $4,513,000 after acquiring an additional 137,691 shares during the period. Rhumbline Advisers grew its position in shares of Esperion Therapeutics by 16.8% during the 2nd quarter. Rhumbline Advisers now owns 275,688 shares of the biopharmaceutical company’s stock valued at $271,000 after acquiring an additional 39,658 shares during the period. Finally, Invesco Ltd. increased its stake in shares of Esperion Therapeutics by 93.3% during the 2nd quarter. Invesco Ltd. now owns 493,929 shares of the biopharmaceutical company’s stock worth $486,000 after purchasing an additional 238,449 shares during the last quarter. Institutional investors own 47.39% of the company’s stock.

Insiders Place Their Bets

In other Esperion Therapeutics news, insider Benjamin Looker sold 11,824 shares of the business’s stock in a transaction on Wednesday, June 17th. The shares were sold at an average price of $3.15, for a total transaction of $37,245.60. Following the sale, the insider owned 667,524 shares of the company’s stock, valued at $2,102,700.60. The trade was a 1.74% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CFO Benjamin Halladay sold 10,773 shares of the stock in a transaction on Wednesday, June 17th. The stock was sold at an average price of $3.15, for a total value of $33,934.95. Following the sale, the chief financial officer owned 702,829 shares in the company, valued at approximately $2,213,911.35. This represents a 1.51% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders own 1.60% of the company’s stock.

Esperion Therapeutics Price Performance

ESPR opened at $3.18 on Tuesday. The company has a market capitalization of $819.45 million, a price-to-earnings ratio of -53.00 and a beta of 1.07. The firm has a 50-day moving average price of $3.16 and a 200-day moving average price of $2.99. Esperion Therapeutics, Inc. has a twelve month low of $1.10 and a twelve month high of $4.18.

Esperion Therapeutics (NASDAQ:ESPR) last announced its quarterly earnings results on Friday, May 8th. The biopharmaceutical company reported ($0.10) EPS for the quarter, missing analysts’ consensus estimates of ($0.02) by ($0.08). The business had revenue of $80.10 million for the quarter, compared to analysts’ expectations of $84.52 million. Esperion Therapeutics had a net margin of 0.12% and a negative return on equity of 0.14%.

Analyst Ratings Changes

A number of research firms recently commented on ESPR. HC Wainwright cut shares of Esperion Therapeutics from a “buy” rating to a “neutral” rating and set a $3.16 price target on the stock. in a report on Friday, May 1st. Weiss Ratings reissued a “sell (d-)” rating on shares of Esperion Therapeutics in a report on Tuesday, April 21st. Needham & Company LLC downgraded Esperion Therapeutics from a “buy” rating to a “hold” rating in a research report on Monday, May 4th. Jefferies Financial Group lowered Esperion Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Friday, May 1st. Finally, Piper Sandler cut Esperion Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Friday, May 1st. One research analyst has rated the stock with a Buy rating, six have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $5.54.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of oral, low–density lipoprotein cholesterol (LDL-C)–lowering therapies. The company’s research and development efforts center on small-molecule compounds designed to address atherosclerotic cardiovascular disease by targeting cholesterol biosynthesis pathways. Esperion seeks to provide novel treatment options for patients who require additional LDL-C reduction beyond what is achieved with statins or who are statin-intolerant.

The company’s lead products include NEXLETOL (bempedoic acid), an oral adenosine triphosphate–citrate lyase (ACL) inhibitor approved by the U.S.